Effect of ADX-88178, a highly-selective mGlu4 PAM, on parkinsonism, dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Objective: To investigate the effect of the metabotropic glutamate 4 (mGlu4) positive allosteric modulator (PAM) ADX-88178 on parkinsonism, dyskinesia and psychosis-like behaviours (PLBs) in the…Identifying delirium in Parkinson’s: evaluation of existing tools and measures
Objective: To evaluate the diagnostic accuracy of tools to identify delirium in inpatients with Parkinson’s disease (PD). Background: Delirium is a serious acute state of…Neuropsychiatric Symptoms in Early-Onset Parkinson’s Disease
Objective: To describe the neuropsychiatric symptoms of Early-Onset Parkinson’s Disease (EOPD) patients in an incident cohort study from 1991 to 2010 in Olmsted County, Minnesota…Olfactory dysfunction and neuropsychiatric manifestations in early drug-naïve Parkinson’s disease
Objective: To determine the severity of various neuropsychiatric disturbances in drug-naïve Parkinson’s disease (PD) patients with (PD-OD) and without olfactory dysfunction (PD-NOD) compared to healthy…Development and Clinimetric Testing Plan for the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)
Objective: Present the development process and clinimetric testing plan for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Psychosis…ER Visits and Hospitalizations Among Patients Treated with Pimavanserin or Other-AAPs for Parkinson’s Disease Psychosis: Analysis of Medicare beneficiaries
Objective: To examine health resource utilization (HRU) outcomes among PDP patients treated with PIMA vs. other AAPs. Background: Real-world analysis demonstrating pimavanserin (PIMA) benefits, the…Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management
Objective: Explore the relationship between multi-domain cognitive testing and patient-reported psychiatric symptoms in PwPD to self-medication management capabilities. Background: Parkinson’s disease (PD) is a complex…Phantom boarder syndrome associated with experimentally-induced presence hallucinations in Parkinson’s disease
Objective: Measuring experimentally-induced presence hallucinations in patients with Parkinson’s disease phantom boarder phenomena. Background: Phantom boarder syndrome (PB) is described as the sensation that someone…Reduced Risk of Mortality and Antipsychotics in Parkinson’s Disease-Related Psychosis: Pimavanserin vs Off-Label Antipsychotics
Objective: Summarize the available data for the mortality risk associated with Parkinson’s disease (PD) psychosis (PDP) and pimavanserin. Background: PDP is associated with increased mortality…Parkinson’s Disease and Psychosocial Impact: Anxiety, Depression and Positive Symptoms
Objective: Explore the relationship between patient self-reported assessment of positive symptoms, depression, and anxiety in PwPD. Background: Parkinson’s disease (PD) is a complex neurodegenerative disorder…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 13
- Next Page »